Business Wire3d
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis and AstraZeneca’s WAINZUA (eplontersen) has been approved in the European Union (EU ...
Medical Dialogues1d
AstraZeneca-Ionis Pharma Wainzua approved in EU for hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
Carlsbad: Ionis Pharma and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment ...
GlobalData on MSN2d
AstraZeneca and Ionis win EU approval for ATTR polyneuropathy
AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...
pharmaphorum3d
EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy
AstraZeneca and Ionis Pharma have an EU green light for their Wainzua therapy for hereditary transthyretin-mediated ...
Zacks.com on MSN2d
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
The latest decision makes Ionis/AstraZeneca's Wainzua the only approved drug in the EU for ATTRv-PN that can be self-administered monthly via an auto-injector.
Ionis and AstraZeneca’s WAINZUA gets EU approval for ATTRv-PN treatment
Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca’s (AZN) WAINZUA eplontersen has been approved in the European Union EU for ...
Nasdaq2d
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
Ionis Pharmaceuticals IONS announced that the European Commission (“EC”) has approved Wainzua (eplontersen) for treating adult patients with hereditary transthyretin-mediated amyloidosis with ...
Nasdaq3d
Ionis Pharma Reports Approval Of WAINZUA In The EU - Quick Facts
(RTTNews) - Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca's WAINZUA has been approved in the European Union for the treatment of hereditary transthyretin-mediated amyloidosis ...
The Pharma Letter3d
EU nod next for ATTRv-PN drug
AstraZeneca and Ionis’ Wainzua (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary ...
Investing3d
Ionis gains EU approval for amyloidosis treatment
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a $5.37 billion market cap biotechnology company, has received approval from the European Union for its treatment WAINZUA, intended for adult patients ...